

Assessing the Burden of Injection with Parenteral Hereditary Angioedema Therapies

Daniel F. Soteres, MD MPH¹; Kristen A. Cribbs, PhD MPH²; Shawn Czado³

¹Asthma & Allergy Associates, PC and Research Center, Colorado Springs, CO, USA; ²Alkemi LLC, Manchester Center, VT, USA; ³KalVista Pharmaceuticals, Inc., Cambridge, MA, USA

Background

- Hereditary angioedema (HAE) is a rare, genetic disease characterized by debilitating swelling episodes in various parts of the body¹
- Currently, most prophylactic HAE treatments and all on-demand HAE treatments are parenteral, requiring intravenous (IV) or subcutaneous (SC) injection, and have been associated with significant burden and adherence challenges¹
- Drug route of administration can impact patient preference, quality of life, disease outcomes, and costs of care²
- As the HAE therapeutic landscape evolves and new treatments emerge, gaining a better understanding of the patient-reported clinical, humanistic, and economic burden of parenteral HAE therapies is critical to facilitating optimal, patient-centered disease management

Methods

- We conducted a targeted literature review (TLR) to assess the clinical, humanistic, and economic burden of on-demand and prophylactic parenteral HAE therapies on individuals living with HAE
- We conducted searches in PubMed and Google Scholar
- We prioritized peer-reviewed articles and conference proceedings published in English from January 1, 2017-November 1, 2022 for inclusion
- We considered older articles, if relevant
- No study design restrictions were applied

Results

- We identified 9 publications.^{1, 3-10} Most studies were observational (78%), peer-reviewed (78%), and conducted in the United States (67%) (**Table 1**)


Table 1. TLR Study and Sample Characteristics

Characteristic	n (%)
Total Number of Publications	9 (100%)
Sample Size, Number of Patients*	
Minimum	30
Maximum	130
Publication Type	
Peer-Reviewed	7 (78%)
Conference Proceeding	2 (22%)
Study Location	
United States	6 (67%)
Multiple	3 (33%)
Study Design	
Observational	7 (78%)
Randomized Controlled Trial	2 (22%)

*All studies reported outcomes among adult patients only

- Patients reported multifaceted challenges associated with a parenteral HAE therapeutic regimen, which impacted treatment adherence
- Patients taking on-demand HAE therapy reported refusing self-administration most commonly due to fear of injection (69%) and lack of skills (47%)³ (**Figure 1**)
- Nearly one-fifth of patients (19%) reported skipping their prophylaxis HAE medication altogether because injections or infusions were inconvenient¹
- The majority of patients (62%) who used a peripheral vein to administer HAE treatment reported difficulty finding a usable vein, and more than half of intravenous prophylaxis users (51%) were dissatisfied with the length of time required to prepare and administer their medication⁸

Figure 1. Commonly Cited Reasons for Refusing On-Demand Self-Administration³



- Nearly half of patients reported feeling nervous when starting new prophylactic treatment (47%)¹ (**Figure 2**)
- Adverse events related to parenteral HAE therapies were also a concern, with one study reporting 98% of patients using on-demand icatibant had injection site reactions.⁴ Common reactions included: pain, bruising, hematoma, burning, numbness, edema, pruritus, and urticaria^{4,5}
- Results also revealed the types of attack-related parenteral HAE therapy costs that burden patients and payers, including healthcare visits and associated travel to obtain treatment as well as the cost of injection supplies, such as syringes and alcohol swabs⁶
- Additionally, patients required significant training to be able to administer on-demand therapies, with half of patients in one study requiring 3-5 training sessions to be able to self-administer³ (**Table 2**)

Figure 2. Prophylactic Parenteral Treatment Impact on Patient Mental Health¹




Table 2. Training Session Required to Self-Administer Parenteral On-Demand Therapies³

Number of Training Sessions Required	Percentage of Patients
1-2	42.7%
3-5	50.0%
6-10	2.8%

Conclusions

- This TLR found that parenteral HAE therapies are burdensome for patients, yielding significant clinical and mental burdens that may impact quality of life
- Fear of injection, lack of skills, and perceived inconvenience of injection were commonly reported, leading to adherence challenges. Injection site reactions were frequently experienced
- Findings also illuminated the economic impact of parenteral HAE therapies on patients and payers, as healthcare services and supports, such as repeated medication administration trainings, were often required
- Novel, easy-to-administer HAE treatments, especially in the on-demand space – where only parenteral therapies exist – provide an opportunity to address unmet patient needs and improve treatment outcomes

References


- Radojicic C, Riedl MA, Craig TJ, et al. Patient perspectives on the treatment burden of injectable medication for hereditary angioedema. *Allergy Asthma Proc.* May 1 2021;42(3):S4-S10. doi:10.2500/aap.2021.42.210025
- Ronquest NA, Paret K, Lucas A, Ciepielewska M, Hagan M. Quantifying the Value of Introducing an Oral Drug Delivery Option for Edoxaban: A Review of Analyses Evaluating the Economic Impact of Oral versus Intravenous Formulations. *Clinicoecon Outcomes Res.* 2022;14:499-511. doi:10.2147/CEOR.S359025
- Tuong LA, Olivier K, Craig TJ. Barriers to self-administered therapy for hereditary angioedema. *Allergy Asthma Proc.* May-Jun 2014;35(3):250-4. doi:10.2500/aap.2014.35.3753
- Lumry WR, Farkas H, Moldovan D, Toubi E, Baptista J, Craig T, Riedl M. Icatibant for Multiple Hereditary Angioedema Attacks across the Controlled and Open-Label Extension Phases of FAST-3. *Int Arch Allergy Immunol.* 2015;168(1):44-55. doi: 10.1159/000441060. Epub 2015 Nov 11. PMID: 26556097.
- Cicardi M, Banerji A, Bracho F, et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. *N Engl J Med.* Aug 5 2010;363(6):532-41. doi:10.1056/NEJMoa0906393
- Bygum A, Aysgören-Pürsün E, Beusterien K, Hautamaki E, Sisic Z, Wai S, Boysen HB, Caballero T. Burden of Illness in Hereditary Angioedema: A Conceptual Model. *Acta Derm Venereol.* 2015 Jul;95(6):706-10. doi: 10.2340/00015555-2014. PMID: 25394853.
- Craig T, Banerji A, Riedl MA, et al. Prophylactic Treatment Burden: Assessment by Caregivers of Patients with Hereditary Angioedema. presented at: 2020 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI); November 13th-15th 2020; Virtual. <https://epostersonline.com/acaa2020/node/1446?view=true>
- Riedl MA, Banerji A, Busse PJ, et al. Patient satisfaction and experience with intravenously administered C1-inhibitor concentrates in the United States. *Ann Allergy Asthma Immunol.* Jul 2017;119(1):59-64. doi:10.1016/j.ana.2017.05.017
- Riedl MA, Craig T, Banerji A, et al. Understanding Differences in Perceptions of Hereditary Angioedema Treatment Burden May Improve Patient-Physician Treatment Care Dialogue. presented at: 2020 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI); November 13th-15th 2020; Virtual. <https://epostersonline.com/acaa2020/node/1449?view=true>
- Wang A, Fouche A, Craig TJ. Patients perception of self-administered medication in the treatment of hereditary angioedema. *Ann Allergy Asthma Immunol.* Aug 2015;115(2):120-5. doi:10.1016/j.ana.2015.06.006

Acknowledgements

The authors thank Alkemi LLC contributors Betsy J. Lahue and Da-In K. Fang, who assisted with abstract writing and editing.

Disclosures

This study was sponsored by KalVista Pharmaceuticals, Inc. SC is an employee of KalVista Pharmaceuticals, Inc. No authors received compensation for their involvement in this research.



Please scan this QR code to view the poster after the congress

